Next-Gen heart defibrillators put to the test
NCT ID NCT07360158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test the safety and performance of a new generation of implantable heart devices called CorSky ICDs and CRT-Ds. These devices help control dangerous heart rhythms in people with heart failure or tachyarrhythmia. About 151 participants will be implanted with the device and monitored for 6 months using home monitoring technology.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CorSky ICD or CRT-D device
What this could lead to
If successful, this could confirm that the new CorSky devices are safe and work well for controlling dangerous heart rhythms.
What could go wrong
This is a post-market study, not a large randomized trial. It only follows 151 people for 6 months, so long-term benefits or rare risks may not be fully captured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.